← Back to All US Stocks

InMode Ltd. (INMD) Stock Fundamental Analysis & AI Rating 2026

INMD Nasdaq Electromedical & Electrotherapeutic Apparatus L3 CIK: 0001742692
Updated This Month • Analysis: Mar 29, 2026 • SEC Data: 2026-03-29
Combined AI Rating
HOLD
42% Confidence
STRONG AGREEMENT
HOLD
5% Conf
HOLD
79% Conf

📊 INMD Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: N/A
Current Ratio: N/A
Debt/Equity: N/A
EPS: $0.00
AI Rating: HOLD with 5% confidence
InMode Ltd. (INMD) receives a HOLD rating with 42% confidence from our AI fundamental analysis based on SEC 10-K filings. Below is our complete INMD stock analysis for 2026.

Is InMode Ltd. (INMD) a Good Investment?

Claude

Unable to conduct fundamental analysis due to complete absence of financial data. All income statement, balance sheet, cash flow, and profitability metrics are unavailable, preventing any meaningful assessment of the company's financial health, profitability trends, or growth quality.

ChatGPT

InMode remains fundamentally strong on balance sheet quality, with $302.5 million of cash, $83.6 million of marketable securities, $169.2 million of short-term deposits, no bank debt, and continued positive free cash flow. The core issue is operating deterioration: revenue has declined for two straight years, gross margin has compressed, and operating income fell materially from 2023 levels, indicating weaker demand and lower earnings quality than the headline cash position suggests. The company is still highly profitable, but the current fundamental picture is best described as financially resilient rather than clearly reaccelerating.

Why Buy InMode Ltd. Stock? INMD Key Strengths

Claude
  • + Company operates in medical device sector (electromedical apparatus) which has structural growth drivers
  • + Listed on Nasdaq suggesting meets exchange listing standards
  • + Zero insider selling activity in last 90 days suggests management confidence
ChatGPT
  • + Very strong net-cash balance sheet with minimal leverage and liabilities far below liquid assets
  • + Still generates high profitability, including roughly 78.5% gross margin and 23.0% operating margin in 2025
  • + Free cash flow remains solid because the business is capital-light, with about $1.0 million of capital expenditures in 2025

INMD Stock Risks: InMode Ltd. Investment Risks

Claude
  • ! No financial data available - unable to assess revenue trends, profitability, or cash generation
  • ! Cannot evaluate balance sheet strength, liquidity position, or leverage levels
  • ! Lack of operating metrics prevents assessment of business fundamentals and operational efficiency
ChatGPT
  • ! Revenue declined from $492.0 million in 2023 to $394.8 million in 2024 to $370.5 million in 2025, showing sustained top-line pressure
  • ! Margin compression is ongoing, with gross margin falling from about 83.6% in 2023 to 80.3% in 2024 to 78.5% in 2025
  • ! Operating cash flow weakened to $85.3 million in 2025 from $132.7 million in 2024 and $176.8 million in 2023, while inventory rose materially

Key Metrics to Watch

Claude
  • * Revenue growth and gross margin trends when data becomes available
  • * Operating cash flow and free cash flow generation
  • * Balance sheet composition including debt levels and cash position
ChatGPT
  • * Revenue growth by geography and consumables mix to confirm whether demand stabilizes
  • * Operating margin and operating cash flow conversion, especially alongside inventory and receivables trends

InMode Ltd. (INMD) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

INMD Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

INMD vs Healthcare Sector: How InMode Ltd. Compares

How InMode Ltd. compares to Healthcare sector averages

Net Margin
INMD 0.0%
vs
Sector Avg 12.0%
INMD Sector
ROE
INMD 0.0%
vs
Sector Avg 15.0%
INMD Sector
Current Ratio
INMD 0.0x
vs
Sector Avg 2.0x
INMD Sector
Debt/Equity
INMD 0.0x
vs
Sector Avg 0.6x
INMD Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is InMode Ltd. Stock Overvalued? INMD Valuation Analysis 2026

Based on fundamental analysis, InMode Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

InMode Ltd. Balance Sheet: INMD Debt, Cash & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

INMD Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

INMD SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for InMode Ltd. (CIK: 0001742692)

📋 Recent SEC Filings

Date Form Document Action
Feb 6, 2024 SC 13G il0011595993_020524.txt View →
May 22, 2020 SC 13G tm2020735d1_sc13g.htm View →
Feb 14, 2020 SC 13G tm207655d2_sc13g.htm View →
Feb 14, 2020 SC 13G tm207655-1_sc13g.htm View →
Feb 14, 2020 SC 13G tm207623-1_sc13g.htm View →

Frequently Asked Questions about INMD

What is the AI rating for INMD?

InMode Ltd. (INMD) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 42% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are INMD's key strengths?

Claude: Company operates in medical device sector (electromedical apparatus) which has structural growth drivers. Listed on Nasdaq suggesting meets exchange listing standards. ChatGPT: Very strong net-cash balance sheet with minimal leverage and liabilities far below liquid assets. Still generates high profitability, including roughly 78.5% gross margin and 23.0% operating margin in 2025.

What are the risks of investing in INMD?

Claude: No financial data available - unable to assess revenue trends, profitability, or cash generation. Cannot evaluate balance sheet strength, liquidity position, or leverage levels. ChatGPT: Revenue declined from $492.0 million in 2023 to $394.8 million in 2024 to $370.5 million in 2025, showing sustained top-line pressure. Margin compression is ongoing, with gross margin falling from about 83.6% in 2023 to 80.3% in 2024 to 78.5% in 2025.

What is INMD's revenue and growth?

InMode Ltd. reported revenue of N/A.

Does INMD pay dividends?

InMode Ltd. does not currently pay dividends.

Where can I find INMD SEC filings?

Official SEC filings for InMode Ltd. (CIK: 0001742692) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is INMD's EPS?

InMode Ltd. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is INMD a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, InMode Ltd. has a HOLD rating with 42% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is INMD stock overvalued or undervalued?

Valuation metrics for INMD: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy INMD stock in 2026?

Our dual AI analysis gives InMode Ltd. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is INMD's free cash flow?

InMode Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.

How does INMD compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 29, 2026 | Data as of: 2026-03-29 | Powered by Claude AI